<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">endoserg</journal-id><journal-title-group><journal-title xml:lang="ru">Эндокринная хирургия</journal-title><trans-title-group xml:lang="en"><trans-title>Endocrine Surgery</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2306-3513</issn><issn pub-type="epub">2310-3965</issn><publisher><publisher-name>Типография «Печатных дел Мастер»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/serg12756</article-id><article-id custom-type="elpub" pub-id-type="custom">endoserg-12756</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Обзоры литературы</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Review of literature</subject></subj-group></article-categories><title-group><article-title>Основные опухоли околощитовидной железы</article-title><trans-title-group xml:lang="en"><trans-title>Main parathyroid tumors</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7616-3899</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гарифуллин</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Garifullin</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гарифуллин Айрат Ильдарович</p><p>SPIN: 3023-1743</p><p>125284, г. Москва, 2-й Боткинский пр., 3</p></bio><bio xml:lang="en"><p>Airat I. Garifullin</p><p>SPIN: 3023-1743</p><p>3 Botkinsky pr., Moscow, 125284</p></bio><email xlink:type="simple">sagidullin12@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3607-6333</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Абсалямова</surname><given-names>Р. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Absaliamova</surname><given-names>R. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Абсалямова Рамиля Миннулловна </p><p>SPIN: 9324-2745</p><p>Уфа</p></bio><bio xml:lang="en"><p>Ramilia M. Absaliamova</p><p>SPIN: 9324-2745</p><p>Ufa</p></bio><email xlink:type="simple">ramilia.absaliamova@yahoo.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7993-4591</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дубинина</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Dubinina</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дубинина Аделя Владимировна </p><p>SPIN: 4013-1953</p><p>Уфа</p></bio><bio xml:lang="en"><p>Adelya V. Dubinina</p><p>SPIN: 4013-1953</p><p>Ufa</p></bio><email xlink:type="simple">ade.vladimirovna@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3580-1612</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Юфанова</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Yufanova</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Юфанова Алина Игоревна</p><p>SPIN: 3693-8712</p><p>Москва</p></bio><bio xml:lang="en"><p>Alina I. Yufanova</p><p>SPIN: 3693-8712</p><p>Moscow</p></bio><email xlink:type="simple">yufanova.lina@yandex.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0118-5812</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Смирнова</surname><given-names>В. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Smirnova</surname><given-names>V. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Смирнова Вера Максимовна</p><p>SPIN: 5251-1424</p><p>Москва</p></bio><bio xml:lang="en"><p>Vera M. Smirnova</p><p>SPIN: 5251-1424</p><p>Moscow</p></bio><email xlink:type="simple">verasmirnova365@yandex.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1306-7282</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ишбулатова</surname><given-names>Ю. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Ishbulatova</surname><given-names>J. T.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ишбулатова Юлия Талгатовна </p><p>SPIN: 7421-1241</p><p>Уфа</p></bio><bio xml:lang="en"><p>Julia T. Ishbulatova</p><p>SPIN: 7421-1241</p><p>Ufa</p></bio><email xlink:type="simple">ishbulatova99@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3501-7016</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шарабарова</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Sharabarova</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шарабарова Мария Владиславовна </p><p>SPIN: 5613-1251</p><p>Уфа</p></bio><bio xml:lang="en"><p>Maria V. Sharabarova</p><p>SPIN: 5613-1251</p><p>Ufa</p></bio><email xlink:type="simple">msharabarova@inbox.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8564-2026</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хуснутдинова</surname><given-names>Э. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Khusnutdinova</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Хуснутдинова Элина Альбертовна </p><p>SPIN: 9327-2113</p><p>Уфа</p></bio><bio xml:lang="en"><p>Elina A. Khusnutdinova</p><p>SPIN: 9327-2113</p><p>Ufa</p></bio><email xlink:type="simple">elina.str@bk.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9567-6086</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сафронова</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Safronova</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сафронова Дарья Викторовна </p><p>SPIN: 2599-9741</p><p>Уфа</p></bio><bio xml:lang="en"><p>Darya S. Safronova</p><p>SPIN: 2599-9741</p><p>Ufa</p></bio><email xlink:type="simple">af_dasha@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0367-1697</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Габдуллина</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Gabdullina</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Габдуллина Анастасия Андреевна </p><p>SPIN: 9029-1312</p><p>Уфа</p></bio><bio xml:lang="en"><p>Anastasiya A. Gabdullina</p><p>SPIN: 9029-1312</p><p>Ufa</p></bio><email xlink:type="simple">anastasya.nastya-karpova@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8893-9271</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Айбулатов</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Aibulatov</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Айбулатов Александр Игоревич</p><p>SPIN: 3339-7754</p><p>Уфа</p></bio><bio xml:lang="en"><p>Alexander I. Aibulatov</p><p>SPIN: 3339-7754</p><p>Ufa</p></bio><email xlink:type="simple">alexanderaibulatov@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2420-2884</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ситдикова</surname><given-names>Д. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Sitdikova</surname><given-names>D. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ситдикова Диана Рифнатовна </p><p>SPIN: 4233-1225</p><p>Уфа</p></bio><bio xml:lang="en"><p>Diana R. Sitdikova</p><p>SPIN: 4233-1225</p><p>Ufa</p></bio><email xlink:type="simple">diana.sitdickova2013@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>P. Hertsen Moscow Oncology Research Institute</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Башкирский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Bashkir state medical university</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Первый Московский государственный медицинский университет им. И.М. Сеченова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical Univesity</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>19</day><month>01</month><year>2023</year></pub-date><volume>16</volume><issue>1</issue><fpage>4</fpage><lpage>12</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гарифуллин А.И., Абсалямова Р.М., Дубинина А.В., Юфанова А.И., Смирнова В.М., Ишбулатова Ю.Т., Шарабарова М.В., Хуснутдинова Э.А., Сафронова Д.В., Габдуллина А.А., Айбулатов А.И., Ситдикова Д.Р., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Гарифуллин А.И., Абсалямова Р.М., Дубинина А.В., Юфанова А.И., Смирнова В.М., Ишбулатова Ю.Т., Шарабарова М.В., Хуснутдинова Э.А., Сафронова Д.В., Габдуллина А.А., Айбулатов А.И., Ситдикова Д.Р.</copyright-holder><copyright-holder xml:lang="en">Garifullin A.I., Absaliamova R.M., Dubinina A.V., Yufanova A.I., Smirnova V.M., Ishbulatova J.T., Sharabarova M.V., Khusnutdinova E.A., Safronova D.V., Gabdullina A.A., Aibulatov A.I., Sitdikova D.R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.surg-endojournals.ru/jour/article/view/12756">https://www.surg-endojournals.ru/jour/article/view/12756</self-uri><abstract><p>Первичный гиперпаратиреоз — это третья по распространенности патология эндокринной системы. Для него характерны повышение уровня паратиреоидного гормона, гиперкальциемия, гиперкальциурия, гипофосфатемия. Среди симптомов отмечают боль в костях, слабость, полиурию и запоры. В большинстве случаев (85%) первичный гиперпаратиреоз вызван солитарной аденомой околощитовидной железы. Другими причинами являются гиперплазия (5%), множественные аденомы (&lt;5%) и рак (&lt;1%). Однако особое внимание в данной статье уделено двум причинам первичного гиперпаратиреоза: аденоме и раку околощитовидной железы, так как они представляют особый интерес как с молекулярной точки зрения, так и в отношении клинических особенностей данных опухолей. Кроме того, данные опухоли пересекаются по своим симптомам и признакам, и диагноз зачастую устанавливается только после гистологического исследования. В общей сложности нами выявлено 2700 статей, из которых 66 соответствовали критериям включения. 66 включенных исследований были тематическими по опухолевым образованиям околощитовидной железы. Они были проведены в период с 1997 по 2022 гг. Обзор подчеркивает важность дальнейшего исследования молекулярных особенностей данных заболеваний и, возможно, таргетных методов лечения, так как, например, при раке околощитовидной железы даже при резекции R0 высок риск рецидива. Также в статье уделено внимание вопросам новой классификации опухолевых поражений околощитовидной железы 2022 г. Всемирной организации здравоохранения , что также важно для унифицированного изучения данных опухолей.</p></abstract><trans-abstract xml:lang="en"><p>Primary hyperparathyroidism is the third most common disease of the endocrine system. It is characterized by an increase in parathyroid hormone, hypercalcemia, hypercalciuria, hypophosphatemia. Symptoms include polyuria, bone pain, weakness, and constipation. In most cases, primary hyperparathyroidism is caused by solitary parathyroid adenoma — 85%. Other causes include hyperplasia (5%), multiple adenomas (&lt;5%), and cancer (&lt;1%). However, particular attention in this article is paid to two causes of primary hyperparathyroidism: parathyroid adenoma and cancer, as they are of high interest both from a molecular point of view and from the clinical features of these tumors. In addition, these tumors overlap in their symptoms and signs and the diagnosis is often made only after histological examination. In total, we identified 2700 articles, of which 66 met the inclusion criteria. The 66 included studies were topical for tumor lesions of the parathyroid gland. They were held between 1997 and 2022. This review emphasizes the importance of further research of the molecular features of these diseases and, possibly, targeted treatment options, since, for example, in cancer, even with R0 resection, the risk of recurrence is high. The article also focuses on the issues of the new World Health Organization 2022 classification of tumor lesions of the parathyroid gland, which is also important for a unified study of these tumors.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>околощитовидные железы</kwd><kwd>паратиреоидные заболевания</kwd><kwd>аденома околощитовидной железы</kwd><kwd>рак околощитовидной железы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>parathyroid glands</kwd><kwd>parathyroid diseasesparathyroid adenoma</kwd><kwd>parathyroid carcinoma</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Madkhali T, Alhefdhi A, Chen H, Elfenbein D. Primary hyperparathyroidism. Turkish J Surg. 2016;32(1):58-66. doi: https://doi.org/10.5152/UCD.2015.3032</mixed-citation><mixed-citation xml:lang="en">Madkhali T, Alhefdhi A, Chen H, Elfenbein D. Primary hyperparathyroidism. Turkish J Surg. 2016;32(1):58-66. doi: https://doi.org/10.5152/UCD.2015.3032</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Yeh MW, Ituarte PH, Zhou HC, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab. 2013;98(3):1122-1129. doi: https://doi.org/10.1210/jc.2012-4022</mixed-citation><mixed-citation xml:lang="en">Yeh MW, Ituarte PH, Zhou HC, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab. 2013;98(3):1122-1129. doi: https://doi.org/10.1210/jc.2012-4022</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Wermers RA, Khosla S, Atkinson EJ, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993–2001: an update on the changing epidemiology of the disease. J Bone Miner Res. 2006;21(1):171-177. doi: https://doi.org/10.1359/JBMR.050910</mixed-citation><mixed-citation xml:lang="en">Wermers RA, Khosla S, Atkinson EJ, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993–2001: an update on the changing epidemiology of the disease. J Bone Miner Res. 2006;21(1):171-177. doi: https://doi.org/10.1359/JBMR.050910</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Мокрышева Н.С., Мирная С.С., Добрева Е.А., и др. Первичный гиперпаратиреоз в России по данным регистра // Проблемы Эндокринологии. – 2019. – Т. 65. – №5. – С. 300-310. doi: https://doi.org/10.14341/probl10126</mixed-citation><mixed-citation xml:lang="en">Mokrysheva NS, Mirnaya SS, Dobreva EA, et al. Primary hyperparathyroidism in Russia according to the registry. Problems of Endocrinology. 2019;65(5):300-310. (In Russ.). doi: https://doi.org/10.14341/probl10126</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Bilezikian JP. Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2018;103(11):3993-4004. doi: https://doi.org/10.1210/jc.2018-01225</mixed-citation><mixed-citation xml:lang="en">Bilezikian JP. Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2018;103(11):3993-4004. doi: https://doi.org/10.1210/jc.2018-01225</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Marcocci C, Cetani F. Clinical practice. Primary hyperparathyroidism. N Engl J Med. 2011;365(25):2389-2397. doi: https://doi.org/10.1056/NEJMcp110663</mixed-citation><mixed-citation xml:lang="en">Marcocci C, Cetani F. Clinical practice. Primary hyperparathyroidism. N Engl J Med. 2011;365(25):2389-2397. doi: https://doi.org/10.1056/NEJMcp110663</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Blau JE, Simonds WF. Familial hyperparathyroidism. Front Endocrinol (Lausanne). 2021;12(1):58-66. doi: https://doi.org/10.3389/fendo.2021.623667</mixed-citation><mixed-citation xml:lang="en">Blau JE, Simonds WF. Familial hyperparathyroidism. Front Endocrinol (Lausanne). 2021;12(1):58-66. doi: https://doi.org/10.3389/fendo.2021.623667</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Mizobuchi M, Ogata H, Koiwa F. Secondary hyperparathyroidism: pathogenesis and latest treatment. Ther Apher Dial. 2019;23(4):309-318. doi: https://doi.org/10.1111/1744-9987.12772</mixed-citation><mixed-citation xml:lang="en">Mizobuchi M, Ogata H, Koiwa F. Secondary hyperparathyroidism: pathogenesis and latest treatment. Ther Apher Dial. 2019;23(4):309-318. doi: https://doi.org/10.1111/1744-9987.12772</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Palmer SC, Mavridis D, Johnson DW, et al. Comparative effectiveness of calcimimetic agents for secondary hyperparathyroidism in adults: A systematic review and network meta-analysis. Am J Kidney Dis. 2020;76(3):321-330. doi: https://doi.org/10.1053/j.ajkd.2020.02.439</mixed-citation><mixed-citation xml:lang="en">Palmer SC, Mavridis D, Johnson DW, et al. Comparative effectiveness of calcimimetic agents for secondary hyperparathyroidism in adults: A systematic review and network meta-analysis. Am J Kidney Dis. 2020;76(3):321-330. doi: https://doi.org/10.1053/j.ajkd.2020.02.439</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Tai TS, Hsu YH, Chang JM, Chen CC. Recurrent tertiary hyperparathyroidism due to supernumerary parathyroid glands in a patient receiving long-term hemodialysis: a case report. BMC Endocr Disord. 2019;19(1):16. doi: https://doi.org/10.1186/s12902-019-0346-7</mixed-citation><mixed-citation xml:lang="en">Tai TS, Hsu YH, Chang JM, Chen CC. Recurrent tertiary hyperparathyroidism due to supernumerary parathyroid glands in a patient receiving long-term hemodialysis: a case report. BMC Endocr Disord. 2019;19(1):16. doi: https://doi.org/10.1186/s12902-019-0346-7</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Dulfer RR, Franssen GJH, Hesselink DA, et al. Systematic review of surgical and medical treatment for tertiary hyperparathyroidism. Br J Surg. 2017;104(7):804-813. doi: https://doi.org/10.1002/bjs.10554</mixed-citation><mixed-citation xml:lang="en">Dulfer RR, Franssen GJH, Hesselink DA, et al. Systematic review of surgical and medical treatment for tertiary hyperparathyroidism. Br J Surg. 2017;104(7):804-813. doi: https://doi.org/10.1002/bjs.10554</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Erickson LA, Mete O, Juhlin CC, et al. Overview of the 2022 WHO classification of parathyroid tumors. Endocr Pathol. 2022;33(1):64-89. doi: https://doi.org/10.1007/s12022-022-09709-1</mixed-citation><mixed-citation xml:lang="en">Erickson LA, Mete O, Juhlin CC, et al. Overview of the 2022 WHO classification of parathyroid tumors. Endocr Pathol. 2022;33(1):64-89. doi: https://doi.org/10.1007/s12022-022-09709-1</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organisation. WHO classification of tumours; endocrine tumours. 5th ed. Lyon, France: International Agency for Research on Cancer; 2022.</mixed-citation><mixed-citation xml:lang="en">World Health Organisation. WHO classification of tumours; endocrine tumours. 5th ed. Lyon, France: International Agency for Research on Cancer; 2022.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Haven CJ, Howell VM, Eilers PHC, et al. gene expression of parathyroid tumors. Cancer Res. 2004;64(20):7405-7411. doi: https://doi.org/10.1158/0008-5472.CAN-04-2063</mixed-citation><mixed-citation xml:lang="en">Haven CJ, Howell VM, Eilers PHC, et al. gene expression of parathyroid tumors. Cancer Res. 2004;64(20):7405-7411. doi: https://doi.org/10.1158/0008-5472.CAN-04-2063</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Sulaiman L, Haglund F, Hashemi J, et al. Genomewide and locus specific alterations in CDC73/HRPT2- mutated parathyroid tumors. PLoS One. 2012;7(9):e46325. doi: https://doi.org/10.1371/journal.pone.0046325</mixed-citation><mixed-citation xml:lang="en">Sulaiman L, Haglund F, Hashemi J, et al. Genomewide and locus specific alterations in CDC73/HRPT2- mutated parathyroid tumors. PLoS One. 2012;7(9):e46325. doi: https://doi.org/10.1371/journal.pone.0046325</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Silva BC, Cusano NE, Bilezikian JP. Primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab. 2018;32(5):593-607. doi: https://doi.org/10.1016/j.beem.2018.09.004</mixed-citation><mixed-citation xml:lang="en">Silva BC, Cusano NE, Bilezikian JP. Primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab. 2018;32(5):593-607. doi: https://doi.org/10.1016/j.beem.2018.09.004</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Guilmette J, Sadow PM. Parathyroid Pathology. Surg Pathol Clin. 2019;12(4):1007-1019. doi: https://doi.org/10.1016/j.path.2019.08.006</mixed-citation><mixed-citation xml:lang="en">Guilmette J, Sadow PM. Parathyroid Pathology. Surg Pathol Clin. 2019;12(4):1007-1019. doi: https://doi.org/10.1016/j.path.2019.08.006</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Leong DCW, Lo J, Nguyen H, Ryan S. Can we predict expected adenoma weight preoperatively with reference to the correlation of preoperative biochemical tests with parathyroid adenoma weight? Asian J Surg. 2020;43(7):759-764. doi: https://doi.org/10.1016/j.asjsur.2019.10.004</mixed-citation><mixed-citation xml:lang="en">Leong DCW, Lo J, Nguyen H, Ryan S. Can we predict expected adenoma weight preoperatively with reference to the correlation of preoperative biochemical tests with parathyroid adenoma weight? Asian J Surg. 2020;43(7):759-764. doi: https://doi.org/10.1016/j.asjsur.2019.10.004</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Erickson LA, Mete O. Immunohistochemistry in diagnostic parathyroid pathology. Endocr Pathol. 2018;29(2):113-129. doi: https://doi.org/10.1007/s12022-018-9527-6</mixed-citation><mixed-citation xml:lang="en">Erickson LA, Mete O. Immunohistochemistry in diagnostic parathyroid pathology. Endocr Pathol. 2018;29(2):113-129. doi: https://doi.org/10.1007/s12022-018-9527-6</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Wilhelm SM, Wang TS, Ruan DT, et al. The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. JAMA Surg. 2016;151(10):959. doi: https://doi.org/10.1001/jamasurg.2016.2310.</mixed-citation><mixed-citation xml:lang="en">Wilhelm SM, Wang TS, Ruan DT, et al. The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. JAMA Surg. 2016;151(10):959. doi: https://doi.org/10.1001/jamasurg.2016.2310.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Romano R, Ellis LS, Yu N, et al. Mutational Analysis of ZFY in Sporadic Parathyroid Adenomas. J Endocr Soc. 2017;1(4):313-316. doi: https://doi.org/10.1210/js.2017-0003122.</mixed-citation><mixed-citation xml:lang="en">Romano R, Ellis LS, Yu N, et al. Mutational Analysis of ZFY in Sporadic Parathyroid Adenomas. J Endocr Soc. 2017;1(4):313-316. doi: https://doi.org/10.1210/js.2017-00031 22.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Alvelos MI, Vinagre J, Fonseca E, et al. MEN1 intragenic deletions may represent the most prevalent somatic event in sporadic primary hyperparathyroidism. Eur J Endocrinol. 2013;168(2):119-128. doi: https://doi.org/10.1530/EJE-12-0327</mixed-citation><mixed-citation xml:lang="en">Alvelos MI, Vinagre J, Fonseca E, et al. MEN1 intragenic deletions may represent the most prevalent somatic event in sporadic primary hyperparathyroidism. Eur J Endocrinol. 2013;168(2):119-128. doi: https://doi.org/10.1530/EJE-12-0327</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Hendy GN, Cole DE. Genetic defects associated with familial and sporadic hyperparathyroidism. Front Horm Res. 2013;(41):149-165. doi: https://doi.org/10.1159/000345675</mixed-citation><mixed-citation xml:lang="en">Hendy GN, Cole DE. Genetic defects associated with familial and sporadic hyperparathyroidism. Front Horm Res. 2013;(41):149-165. doi: https://doi.org/10.1159/000345675</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Newey PJ, Nesbit MA, Rimmer AJ, et al. Whole-exome sequencing studies of nonhereditary (sporadic) parathyroid adenomas. J Clin Endocrinol Metab. 2012;97(10):E1995-E2005. doi: https://doi.org/10.1210/jc.2012-2303</mixed-citation><mixed-citation xml:lang="en">Newey PJ, Nesbit MA, Rimmer AJ, et al. Whole-exome sequencing studies of nonhereditary (sporadic) parathyroid adenomas. J Clin Endocrinol Metab. 2012;97(10):E1995-E2005. doi: https://doi.org/10.1210/jc.2012-2303</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Juhlin CC, Erickson LA. Genomics and epigenomics in parathyroid neoplasia: from bench to surgical pathology practice. Endocr Pathol. 2021;32(1):17-34. doi: https://doi.org/10.1007/s12022-020-09656-9</mixed-citation><mixed-citation xml:lang="en">Juhlin CC, Erickson LA. Genomics and epigenomics in parathyroid neoplasia: from bench to surgical pathology practice. Endocr Pathol. 2021;32(1):17-34. doi: https://doi.org/10.1007/s12022-020-09656-9</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Alvelos MI, Mendes M, Soares P. Molecular alterations in sporadic primary hyperparathyroidism. Genet Res Int. 2011;2011(2):1-7. doi: https://doi.org/10.4061/2011/275802</mixed-citation><mixed-citation xml:lang="en">Alvelos MI, Mendes M, Soares P. Molecular alterations in sporadic primary hyperparathyroidism. Genet Res Int. 2011;2011(2):1-7. doi: https://doi.org/10.4061/2011/275802</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Pandya C, Uzilov A V., Bellizzi J, et al. Genomic profiling reveals mutational landscape in parathyroid carcinomas. JCI Insight. 2017;2(6):e92061. doi: https://doi.org/10.1172/jci.insight.92061</mixed-citation><mixed-citation xml:lang="en">Pandya C, Uzilov A V., Bellizzi J, et al. Genomic profiling reveals mutational landscape in parathyroid carcinomas. JCI Insight. 2017;2(6):e92061. doi: https://doi.org/10.1172/jci.insight.92061</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Mallya SM, Gallagher JJ, Wild YK, et al. Abnormal parathyroid cell proliferation precedes biochemical abnormalities in a mouse model of primary hyperparathyroidism. Mol Endocrinol. 2005;19(10):2603-2609. doi: https://doi.org/10.1210/me.2005-0116</mixed-citation><mixed-citation xml:lang="en">Mallya SM, Gallagher JJ, Wild YK, et al. Abnormal parathyroid cell proliferation precedes biochemical abnormalities in a mouse model of primary hyperparathyroidism. Mol Endocrinol. 2005;19(10):2603-2609. doi: https://doi.org/10.1210/me.2005-0116</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Brewer K, Costa-Guda J, Arnold A. Molecular genetic insights into sporadic primary hyperparathyroidism. Endocr Relat Cancer. 2019;26(2):R53-R72. doi: https://doi.org/10.1530/ERC-18-0304</mixed-citation><mixed-citation xml:lang="en">Brewer K, Costa-Guda J, Arnold A. Molecular genetic insights into sporadic primary hyperparathyroidism. Endocr Relat Cancer. 2019;26(2):R53-R72. doi: https://doi.org/10.1530/ERC-18-0304</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Ullah A, Khan J, Waheed A, et al. Parathyroid carcinoma: Incidence, survival analysis, and management: A study from the SEER database and insights into future therapeutic perspectives. Cancers (Basel). 2022;14(6):1426. doi: https://doi.org/10.3390/cancers14061426</mixed-citation><mixed-citation xml:lang="en">Ullah A, Khan J, Waheed A, et al. Parathyroid carcinoma: Incidence, survival analysis, and management: A study from the SEER database and insights into future therapeutic perspectives. Cancers (Basel). 2022;14(6):1426. doi: https://doi.org/10.3390/cancers14061426</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Machado NN, Wilhelm SM. Parathyroid cancer: A review. Cancers (Basel). 2019;11(11):1676. doi: https://doi.org/10.3390/cancers11111676</mixed-citation><mixed-citation xml:lang="en">Machado NN, Wilhelm SM. Parathyroid cancer: A review. Cancers (Basel). 2019;11(11):1676. doi: https://doi.org/10.3390/cancers11111676</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Wang L, Han D, Chen W, et al. Non-functional parathyroid carcinoma: a case report and review of the literature. Cancer Biol Ther. 2015;16(11):1569-1576. doi: https://doi.org/10.1080/15384047.2015.1070989</mixed-citation><mixed-citation xml:lang="en">Wang L, Han D, Chen W, et al. Non-functional parathyroid carcinoma: a case report and review of the literature. Cancer Biol Ther. 2015;16(11):1569-1576. doi: https://doi.org/10.1080/15384047.2015.1070989</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Wei CH, Harari A. Parathyroid carcinoma: update and guidelines for management. Curr Treat Options Oncol. 2012;13(1):11-23. doi: https://doi.org/10.1007/s11864-011-0171-3</mixed-citation><mixed-citation xml:lang="en">Wei CH, Harari A. Parathyroid carcinoma: update and guidelines for management. Curr Treat Options Oncol. 2012;13(1):11-23. doi: https://doi.org/10.1007/s11864-011-0171-3</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Koea JB, Shaw JH. Parathyroid cancer: biology and management. Surg Oncol. 1999;8(3):155-165. doi: https://doi.org/10.1016/s0960-7404(99)00037-7</mixed-citation><mixed-citation xml:lang="en">Koea JB, Shaw JH. Parathyroid cancer: biology and management. Surg Oncol. 1999;8(3):155-165. doi: https://doi.org/10.1016/s0960-7404(99)00037-7</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Williams MD, DeLellis RA, Erickson LA, et al. Pathology data set for reporting parathyroid carcinoma and atypical parathyroid neoplasm: recommendations from the International Collaboration on Cancer Reporting. Hum Pathol. 2021;110(11):73-82. doi: https://doi.org/10.1016/j.humpath.2020.07.008</mixed-citation><mixed-citation xml:lang="en">Williams MD, DeLellis RA, Erickson LA, et al. Pathology data set for reporting parathyroid carcinoma and atypical parathyroid neoplasm: recommendations from the International Collaboration on Cancer Reporting. Hum Pathol. 2021;110(11):73-82. doi: https://doi.org/10.1016/j.humpath.2020.07.008</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Harari A, Waring A, Fernandez-Ranvier G, et al. Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab. 2011;96(12):3679-3686. doi: https://doi.org/10.1210/jc.2011-1571</mixed-citation><mixed-citation xml:lang="en">Harari A, Waring A, Fernandez-Ranvier G, et al. Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab. 2011;96(12):3679-3686. doi: https://doi.org/10.1210/jc.2011-1571</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Cetani F, Pardi E, Marcocci C. Update on parathyroid carcinoma. J Endocrinol Invest. 2016;39(6):595-606. doi: https://doi.org/10.1007/s40618-016-0447-3</mixed-citation><mixed-citation xml:lang="en">Cetani F, Pardi E, Marcocci C. Update on parathyroid carcinoma. J Endocrinol Invest. 2016;39(6):595-606. doi: https://doi.org/10.1007/s40618-016-0447-3</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Sharretts JM, Simonds WF. Clinical and molecular genetics of parathyroid neoplasms. Best Pract Res Clin Endocrinol Metab. 2010;24(3):491-502. doi: https://doi.org/10.1016/j.beem.2010.01.003</mixed-citation><mixed-citation xml:lang="en">Sharretts JM, Simonds WF. Clinical and molecular genetics of parathyroid neoplasms. Best Pract Res Clin Endocrinol Metab. 2010;24(3):491-502. doi: https://doi.org/10.1016/j.beem.2010.01.003</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Cetani F, Marcocci C, Torregrossa L, Pardi E. Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors. Endocr Relat Cancer. 2019;26(7):R441-R464. doi: https://doi.org/10.1530/ERC-19-0135</mixed-citation><mixed-citation xml:lang="en">Cetani F, Marcocci C, Torregrossa L, Pardi E. Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors. Endocr Relat Cancer. 2019;26(7):R441-R464. doi: https://doi.org/10.1530/ERC-19-0135</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Cetani F, Banti C, Pardi E, et al. CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer. Endocr Connect. 2013;2(4):186-195. doi: https://doi.org/10.1530/EC-13-0046</mixed-citation><mixed-citation xml:lang="en">Cetani F, Banti C, Pardi E, et al. CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer. Endocr Connect. 2013;2(4):186-195. doi: https://doi.org/10.1530/EC-13-0046</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Asare EA, Silva-Figueroa A, Hess KR, et al. Risk of distant metastasis in parathyroid carcinoma and its effect on survival: A retrospective review from a highvolume center. Ann Surg Oncol. 2019;26(11):3593-3599. doi: https://doi.org/10.1245/s10434-019-07451-3</mixed-citation><mixed-citation xml:lang="en">Asare EA, Silva-Figueroa A, Hess KR, et al. Risk of distant metastasis in parathyroid carcinoma and its effect on survival: A retrospective review from a highvolume center. Ann Surg Oncol. 2019;26(11):3593-3599. doi: https://doi.org/10.1245/s10434-019-07451-3</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Costa-Guda J, Imanishi Y, Palanisamy N, et al. Allelic imbalance in sporadic parathyroid carcinoma and evidence for its de novo origins. Endocrine. 2013;44(2):489-495. doi: https://doi.org/10.1007/s12020-013-9903-4</mixed-citation><mixed-citation xml:lang="en">Costa-Guda J, Imanishi Y, Palanisamy N, et al. Allelic imbalance in sporadic parathyroid carcinoma and evidence for its de novo origins. Endocrine. 2013;44(2):489-495. doi: https://doi.org/10.1007/s12020-013-9903-4</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339(6127):1546-1558. doi: https://doi.org/10.1126/science.1235122</mixed-citation><mixed-citation xml:lang="en">Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339(6127):1546-1558. doi: https://doi.org/10.1126/science.1235122</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Pardi E, Marcocci C, Borsari S, et al. Aryl hydrocarbon receptor interacting protein (AIP) mutations occur rarely in sporadic parathyroid adenomas. J Clin Endocrinol Metab. 2013;98(7):2800-2810. doi: https://doi.org/10.1210/jc.2012-4029</mixed-citation><mixed-citation xml:lang="en">Pardi E, Marcocci C, Borsari S, et al. Aryl hydrocarbon receptor interacting protein (AIP) mutations occur rarely in sporadic parathyroid adenomas. J Clin Endocrinol Metab. 2013;98(7):2800-2810. doi: https://doi.org/10.1210/jc.2012-4029</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Kang H, Pettinga D, Schubert AD, et al. Genomic profiling of parathyroid carcinoma reveals genomic alterations suggesting benefit from therapy. Oncologist. 2019;24(6):791-797. doi: https://doi.org/10.1634/theoncologist.2018-0334</mixed-citation><mixed-citation xml:lang="en">Kang H, Pettinga D, Schubert AD, et al. Genomic profiling of parathyroid carcinoma reveals genomic alterations suggesting benefit from therapy. Oncologist. 2019;24(6):791-797. doi: https://doi.org/10.1634/theoncologist.2018-0334</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Sun W, Kuang XL, Liu YP, et al. Crystal structure of the N-terminal domain of human CDC73 and its implications for the hyperparathyroidism-jaw tumor (HPT-JT) syndrome. Sci Rep. 2017;7(1):15638. doi: https://doi.org/10.1038/s41598-017-15715-9</mixed-citation><mixed-citation xml:lang="en">Sun W, Kuang XL, Liu YP, et al. Crystal structure of the N-terminal domain of human CDC73 and its implications for the hyperparathyroidism-jaw tumor (HPT-JT) syndrome. Sci Rep. 2017;7(1):15638. doi: https://doi.org/10.1038/s41598-017-15715-9</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y, Zhang J, Adikaram PR, et al. Genotype of CDC73 germline mutation determines risk of parathyroid cancer. Endocr Relat Cancer. 2020;27(9):483-494. doi: https://doi.org/10.1530/ERC-20-0149</mixed-citation><mixed-citation xml:lang="en">Li Y, Zhang J, Adikaram PR, et al. Genotype of CDC73 germline mutation determines risk of parathyroid cancer. Endocr Relat Cancer. 2020;27(9):483-494. doi: https://doi.org/10.1530/ERC-20-0149</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Krebs LJ, Shattuck TM, Arnold A. HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J Clin Endocrinol Metab. 2005;90(9):5015-5017. doi: https://doi.org/10.1210/jc.2005-0717</mixed-citation><mixed-citation xml:lang="en">Krebs LJ, Shattuck TM, Arnold A. HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J Clin Endocrinol Metab. 2005;90(9):5015-5017. doi: https://doi.org/10.1210/jc.2005-0717</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Ryhänen EM, Leijon H, Metso S, et al. A nationwide study on parathyroid carcinoma. Acta Oncol. 2017;56(7):991-1003. doi: https://doi.org/10.1080/0284186X.2017.1306103</mixed-citation><mixed-citation xml:lang="en">Ryhänen EM, Leijon H, Metso S, et al. A nationwide study on parathyroid carcinoma. Acta Oncol. 2017;56(7):991-1003. doi: https://doi.org/10.1080/0284186X.2017.1306103</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Karaarslan S, Yurum FN, Kumbaraci BS, et al. The role of parafibromin, Galectin-3, HBME-1, and Ki-67 in the differential diagnosis of parathyroid tumors. Oman Med J. 2015;30(6):421-427. doi: https://doi.org/10.5001/omj.2015.84</mixed-citation><mixed-citation xml:lang="en">Karaarslan S, Yurum FN, Kumbaraci BS, et al. The role of parafibromin, Galectin-3, HBME-1, and Ki-67 in the differential diagnosis of parathyroid tumors. Oman Med J. 2015;30(6):421-427. doi: https://doi.org/10.5001/omj.2015.84</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Truran PP, Johnson SJ, Bliss RD, et al. Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer. World J Surg. 2014;38(11):2845-2854. doi: https://doi.org/10.1007/s00268-014-2700-2</mixed-citation><mixed-citation xml:lang="en">Truran PP, Johnson SJ, Bliss RD, et al. Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer. World J Surg. 2014;38(11):2845-2854. doi: https://doi.org/10.1007/s00268-014-2700-2</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Shattuck TM, Kim TS, Costa J, et al. Mutational analyses of RB and BRCA2 as candidate tumour suppressor genes in parathyroid carcinoma. Clin Endocrinol (Oxf ). 2003;59(2):180-189. doi: https://doi.org/10.1046/j.1365-2265.2003.01814.x</mixed-citation><mixed-citation xml:lang="en">Shattuck TM, Kim TS, Costa J, et al. Mutational analyses of RB and BRCA2 as candidate tumour suppressor genes in parathyroid carcinoma. Clin Endocrinol (Oxf ). 2003;59(2):180-189. doi: https://doi.org/10.1046/j.1365-2265.2003.01814.x</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Cardoso L, Stevenson M, Thakker RV. Molecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma. Hum Mutat. 2017;38(12):1621-1648. doi: https://doi.org/10.1002/humu.23337</mixed-citation><mixed-citation xml:lang="en">Cardoso L, Stevenson M, Thakker RV. Molecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma. Hum Mutat. 2017;38(12):1621-1648. doi: https://doi.org/10.1002/humu.23337</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Kytölä S, Farnebo F, Obara T, et al. Patterns of chromosomal imbalances in parathyroid carcinomas. Am J Pathol. 2000;157(2):579-586. doi: https://doi.org/10.1016/S0002-9440(10)64568-3</mixed-citation><mixed-citation xml:lang="en">Kytölä S, Farnebo F, Obara T, et al. Patterns of chromosomal imbalances in parathyroid carcinomas. Am J Pathol. 2000;157(2):579-586. doi: https://doi.org/10.1016/S0002-9440(10)64568-3</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Adam MA, Untch BR, Olson JA Jr. Parathyroid carcinoma: current understanding and new insights into gene expression and intraoperative parathyroid hormone kinetics. Oncologist. 2010;15(1):61-72. doi: https://doi.org/10.1634/theoncologist.2009-0185</mixed-citation><mixed-citation xml:lang="en">Adam MA, Untch BR, Olson JA Jr. Parathyroid carcinoma: current understanding and new insights into gene expression and intraoperative parathyroid hormone kinetics. Oncologist. 2010;15(1):61-72. doi: https://doi.org/10.1634/theoncologist.2009-0185</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao J, Hu Y, Liao Q, et al. Gene identification of potential malignant parathyroid tumors phenotype in Chinese population. Endocr J. 2014;61(6):597-605. doi: https://doi.org/10.1507/endocrj.ej14-0023</mixed-citation><mixed-citation xml:lang="en">Zhao J, Hu Y, Liao Q, et al. Gene identification of potential malignant parathyroid tumors phenotype in Chinese population. Endocr J. 2014;61(6):597-605. doi: https://doi.org/10.1507/endocrj.ej14-0023</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Fingeret AL. Contemporary evaluation and management of parathyroid carcinoma. JCO Oncol Pract. 2021;17(1):17-21. doi: https://doi.org/10.1200/JOP.19.00540</mixed-citation><mixed-citation xml:lang="en">Fingeret AL. Contemporary evaluation and management of parathyroid carcinoma. JCO Oncol Pract. 2021;17(1):17-21. doi: https://doi.org/10.1200/JOP.19.00540</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Sali AP, Motghare P, Bal M, et al. Parathyroid carcinoma: A single-institution experience with an emphasis on histopathological features. Head Neck Pathol. 2021;15(2):544-554. doi: https://doi.org/10.1007/s12105-020-01244-x</mixed-citation><mixed-citation xml:lang="en">Sali AP, Motghare P, Bal M, et al. Parathyroid carcinoma: A single-institution experience with an emphasis on histopathological features. Head Neck Pathol. 2021;15(2):544-554. doi: https://doi.org/10.1007/s12105-020-01244-x</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Sawhney S, Vaish R, Jain S, et al. Parathyroid carcinoma: a review. Indian J Surg Oncol. 2022;13(1):133-142. doi: https://doi.org/10.1007/s13193-021-01343-3</mixed-citation><mixed-citation xml:lang="en">Sawhney S, Vaish R, Jain S, et al. Parathyroid carcinoma: a review. Indian J Surg Oncol. 2022;13(1):133-142. doi: https://doi.org/10.1007/s13193-021-01343-3</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Sandelin K, Auer G, Bondeson L, et al. Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg. 1992;16(4):724-731. doi: https://doi.org/10.1007/BF02067369</mixed-citation><mixed-citation xml:lang="en">Sandelin K, Auer G, Bondeson L, et al. Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg. 1992;16(4):724-731. doi: https://doi.org/10.1007/BF02067369</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Hundahl SA, Fleming ID, Fremgen AM, Menck HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1999;86(3):538-544. doi: https://doi.org/10.1002/(sici)1097-0142(19990801)86:33.0.co;2-k</mixed-citation><mixed-citation xml:lang="en">Hundahl SA, Fleming ID, Fremgen AM, Menck HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1999;86(3):538-544. doi: https://doi.org/10.1002/(sici)1097- 0142(19990801)86:33.0.co;2-k</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Lo WM, Good ML, Nilubol N, et al. Tumor size and presence of metastatic disease at diagnosis are associated with diseasespecific survival in parathyroid carcinoma. Ann Surg Oncol. 2018;25(9):2535-2540. doi: https://doi.org/10.1245/s10434-018-6559-6</mixed-citation><mixed-citation xml:lang="en">Lo WM, Good ML, Nilubol N, et al. Tumor size and presence of metastatic disease at diagnosis are associated with diseasespecific survival in parathyroid carcinoma. Ann Surg Oncol. 2018;25(9):2535-2540. doi: https://doi.org/10.1245/s10434-018-6559-6</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Young S, Wu JX, Li N, et al. More extensive surgery may not improve survival over parathyroidectomy alone in parathyroid carcinoma. Ann Surg Oncol. 2016;23(9):2898-2904. doi: https://doi.org/10.1245/s10434-016-5256-6</mixed-citation><mixed-citation xml:lang="en">Young S, Wu JX, Li N, et al. More extensive surgery may not improve survival over parathyroidectomy alone in parathyroid carcinoma. Ann Surg Oncol. 2016;23(9):2898-2904. doi: https://doi.org/10.1245/s10434-016-5256-6</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">McClenaghan F, Qureshi YA. Parathyroid cancer. Gland Surg. 2015;4(4):329-338. doi: https://doi.org/10.3978/j.issn.2227-684X.2015.05.09</mixed-citation><mixed-citation xml:lang="en">McClenaghan F, Qureshi YA. Parathyroid cancer. Gland Surg. 2015;4(4):329-338. doi: https://doi.org/10.3978/j.issn.2227-684X.2015.05.09</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Shane E. Clinical review 122: Parathyroid carcinoma. J Clin Endocrinol Metab. 2001;86(2):485-493. doi: https://doi.org/10.1210/jcem.86.2.7207</mixed-citation><mixed-citation xml:lang="en">Shane E. Clinical review 122: Parathyroid carcinoma. J Clin Endocrinol Metab. 2001;86(2):485-493. doi: https://doi.org/10.1210/jcem.86.2.7207</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Kim KM, Park JB, Bae KS, Kang SJ. Hungry bone syndrome after parathyroidectomy of a minimally invasive parathyroid carcinoma. J Korean Surg Soc. 2011;81(5):344-349. doi: https://doi.org/10.4174/jkss.2011.81.5.344</mixed-citation><mixed-citation xml:lang="en">Kim KM, Park JB, Bae KS, Kang SJ. Hungry bone syndrome after parathyroidectomy of a minimally invasive parathyroid carcinoma. J Korean Surg Soc. 2011;81(5):344-349. doi: https://doi.org/10.4174/jkss.2011.81.5.344</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Jain N, Reilly RF. Hungry bone syndrome. Curr Opin Nephrol Hypertens. 2017;26(4):250-255. doi: https://doi.org/10.1097/MNH.0000000000000327</mixed-citation><mixed-citation xml:lang="en">Jain N, Reilly RF. Hungry bone syndrome. Curr Opin Nephrol Hypertens. 2017;26(4):250-255. doi: https://doi.org/10.1097/MNH.0000000000000327</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Kleinpeter KP, Lovato JF, Clark PB, et al. Is parathyroid carcinoma indeed a lethal disease? Ann Surg Oncol. 2005;12(3):260-266. doi: https://doi.org/10.1245/ASO.2005.03.036</mixed-citation><mixed-citation xml:lang="en">Kleinpeter KP, Lovato JF, Clark PB, et al. Is parathyroid carcinoma indeed a lethal disease? Ann Surg Oncol. 2005;12(3):260-266. doi: https://doi.org/10.1245/ASO.2005.03.036</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Sharretts JM, Kebebew E, Simonds WF. Parathyroid cancer. Semin Oncol. 2010;37(6):580-590. doi: https://doi.org/10.1053/j.seminoncol.2010.10.013</mixed-citation><mixed-citation xml:lang="en">Sharretts JM, Kebebew E, Simonds WF. Parathyroid cancer. Semin Oncol. 2010;37(6):580-590. doi: https://doi.org/10.1053/j.seminoncol.2010.10.013</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Cui M, Hu Y, Bi Y, et al. Preliminary exploration of potential molecular therapeutic targets in recurrent and metastatic parathyroid carcinomas. Int J Cancer. 2019;144(3):525-532. doi: https://doi.org/10.1002/ijc.31948</mixed-citation><mixed-citation xml:lang="en">Cui M, Hu Y, Bi Y, et al. Preliminary exploration of potential molecular therapeutic targets in recurrent and metastatic parathyroid carcinomas. Int J Cancer. 2019;144(3):525-532. doi: https://doi.org/10.1002/ijc.31948</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
